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Abstract
Multiple Sclerosis (MS) is the most common progressive and disabling neurological condition affecting young adults in the
world today. From a genetic point of view, MS is a complex disorder resulting from the combination of genetic and non-
genetic factors. We aimed to identify previously unidentified loci conducting a new GWAS of Multiple Sclerosis (MS) in a
sample of 296 MS cases and 801 controls from the Spanish population. Meta-analysis of our data in combination with
previous GWAS was done. A total of 17 GWAS-significant SNPs, corresponding to three different loci were identified:HLA,
IL2RA, and 5p13.1. All three have been previously reported as GWAS-significant. We confirmed our observation in 5p13.1 for
rs9292777 using two additional independent Spanish samples to make a total of 4912 MS cases and 7498 controls
(ORpooled=0.84; 95%CI: 0.80–0.89; p=1.36610-9). This SNP differs from the one reported within this locus in a recent
GWAS. Although it is unclear whether both signals are tapping the same genetic association, it seems clear that this locus
plays an important role in the pathogenesis of MS.
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Introduction
Multiple Sclerosis (MS) is the most common progressive and
disabling neurological condition affecting young adults in the
world today. The overall prevalence of MS is about 70 per
100,000 individuals (range from 2 to 150) [1]. Pathogenetically,
MS is considered an inflammatory and autoimmune disease with
secondary demyelination during the first years of disease progress,
which often presents clinically with relapsing/remitting symptoms.
After this phase, axonal loss occurs contributing to a secondary
progressive course of the disease [2].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36140From a genetic point of view, MS is a complex disorder
resulting from the combination of genetic and non-genetic factors
[3]. Human leukocyte antigen (HLA) at 6p21 has long been
recognized as the strongest locus increasing risk to MS in most
populations [4]. More recently, at least two independent signals
within the HLA chromosomal region have been reported [5].
Other genetic factors involved in MS have remained elusive until
the arrival of Genome-Wide Association studies (GWAS) which
facilitated the identification of new susceptibility loci (The
MSGene Database. http://www.msgene.org/).
We aimed to identify previously unidentified loci conducting a
new GWAS of Multiple Sclerosis (MS) in a sample of 296 MS
cases and 801 controls from the Spanish population. Meta-analysis
of our data in combination with previous GWAS was also
planned. (Figure S1)
Results
We analysed this new Spanish GWAS (named as the Macarena
dataset) independently, but also in combination with the IMSGC/
WTCCC and the Gene MSA datasets, looking for consistent
genetic factors associated in all datasets. Briefly, we genotyped 296
MS patients and 801 controls from Spain using the Affymetrix
250K Nsp I array as previously described [6]. After an extensive
quality control, we performed principal components analysis
(PCA) [7] and selected for analyses 286 MS cases and 767 controls
described below. We also analyzed a dataset (named hereafter
IMSGC/WT) based on 931 MS cases from the International
Multiple Sclerosis Genetic Consortium (IMSGC) [8] and 2938
controls from the Wellcome Trust Case Control Consortium
(WTCCC), who had been genotyped using Affymetrix 500K array
[9]. After extensive quality control and PCA pruning, similar to
what we applied to the Macarena dataset, a total 886 cases and
2933 controls were considered for downstream analyses. Further-
more, the Gene MSA study [10] was incorporated as a third study
group. Given that the Gene MSA series had been genotyped using
the Sentrix HumanHap550 BeadChip platform from Illumina, we
imputed ,2.5 million markers from HapMap2 to this dataset
using PLINK [11]. Genotypes on associated SNPs were also
corroborated with a second imputation methodology (Mach v 1.0)
[12]. Effective sample size after PCA and genotype quality control
for Gene MSA was 955 MS cases and 858 controls.
We then performed a meta-analysis of these three GWAS
datasets on the 130,903 shared SNPs (Figure 1 and Figure 2), and
selected markers associated with a p-value below 0.005 in the
random effects model for further analyses. While this threshold is
much less stringent than the common GWAS threshold or that of
a Bonferroni correction, we thought to promote a wider list of
SNPs as in a two-stage analysis given the availability of an ‘‘in-
silico’’ replication. A total of 1,064 SNPs meeting this criterion
were indeed analyzed ‘‘in silico’’ in a recent GWAS performed on
882 MS cases and 872 controls from the Sardinian population
[13]. After integrating these data in a new meta-analysis, we found
that 17 markers reached the bonferroni significance of 3.82610-7
(Table 1). Most of these markers (15 of them) were located within
the HLA region, and the remaining two markers were located
within the IL2RA gene (rs12722489, p=2.16610-7) and the
5p13.1 regulatory region near PTGER4 (rs9292777, p=9.84610-
9), respectively. Both HLA and IL2RA are well established MS risk
loci (www.msgene.org). PTGER4 has been previously found to be
associated with Crohn’s disease [9,14,15,16], reported as ‘‘sugges-
tive signal’’ in a meta-analysis of MS GWAS [17], and also
reported as genome-wide significant for MS in a recent GWAS by
the International Multiple Sclerosis Genetics Consortium/Well-
come Trust Case Control Consortium. The marker reported in
this study (rs4613763) [18] is about 45 kb from our marker, with a
D9 of 1 and r
2 of 0.13, so they may not be necessarily tapping the
same genetic association. Indeed a conditional analysis shows
independent effects of rs9292777 in two of the three GWAS
datasets (rs4613763 could not be imputed in Macarena dataset).
Thus, after conditioning on rs4613763 the p-value of rs9292777
went from the original 0.0003 to 0.0039 in IMSGC/WTCCC and
from 0.0019 to 0.0012 in Gene MSA. The corresponding p-values
of rs4613763 before and after conditioning on rs9292777 in the
same two GWAS went from 0.00186 to 0.064 and from 0.826 to
0.335 respectively.
To further validate this marker we considered two independent
samples from the Spanish population, namely the HCSC and the
IPBLN samples. They included 646 and 1257 MS patients, and
746 and 1322 controls respectively.. These healthy controls were
matched to cases by age, gender, ethnicity and place of
recruitment [19]. The selected SNP rs9292777 was imputed in
the HCSC sample and genotyped in the IPBLN sample, using
Taqman technology as described elsewhere. The respective ORs
for rs9292777 were 0.92 (95% CI: 0.79–1.07, p=0.29) and 0.87
(95% CI: 0.78–0.98, p=0.02).
All available evidence from the GWAS datasets and the
validation samples were combined in a final meta-analysis that
included a total of 4912 MS cases and 7498 controls. Overall, the
C allele of rs9292777 was associated with an OR of 0.84 (95%CI:
0.80–0.89) corresponding to a p-value of 1.36610-9, below the
5610-8 Genome-wide significant cutoff. (Figure 3)
To further determine if the MS associated SNPs at the 5p13.1
locus could have a functional effect on the transcription of the
genes located in the region, we assessed eQTLs in the chr5:
39885067-40883829 (NCBI37/hg19) locus by spearman rank
correlation test for association between SNP genotypes of the
region and mRNA levels of 5 genes in the region (TTC33,
PRKAA1, PTGER4, CARD6, RPL37). The expression of the genes
was assayed by Illumina Human-6 v2 Expression BeadChip with
RNA samples from 109 lymphoblastoid cell lines from Utah
residents with Northern and Western European ancestry from the
CEPH collection (HapMap CEU population). Since the CEU
samples were sequenced by the 1000 Genomes project, we
downloaded the variant information from the 1000 Genomes
database. 2593 SNPs and 671 insertion/deletion variants with a
MAF.0.05 were correlated with the expression of the 5 genes.
Significant thresholds for each population were assigned through
1000 permutations. At the 0.05 permutation threshold, we
observed 2 SNPs that were significantly associated with PTGER4
expression (rs7725052 and rs7714574) (Table S1). These 2 SNPs
are in almost total linkage disequilibrium (LD)and are located 193-
187 Kbp from the PTGR4 gene. Other eQTLs in the region
reported by other authors were also explored. Several SNPs
located in position chr5:39,904,511-40,111,728 (NCBI37/hg19)
have been reported to be eQTLs for PTGER4 by Zeller et al [20].
These eQTLs are within 605 to 811 Kbp from the PTGR4 gene
and are different SNPs than the eQTLs found by us in the CEU
samples. Expression QTLs for the RPL37 gene in the region
chr5:40,723,806-40,790,598 (NCBI37/hg19) were also reported
by Stranger et al. [21] and by Dixon et al. [22] as shown in
Figure 4. Since none of the MS associated SNPs were eQTLs for
any of the genes in the region (Figure S2), we analyzed their LD
with the associated variants. There is no LD between the distal
PTGER4 eQTLs, the RPL37 eQTLs and the SNPs reported
associated with Crohn by GWAS or the variants associated with
MS (Figure S3). However, the PTGER4 eQTLs obtained in the
CEU population were in LD with the rs9292777 (r
2=0.23). A
GWAS of MS Confirms a Novel Locus at 5p13.1
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36140Figure 1. Manhattan plot of Meta-Analysis of three GWAS datasets (Macarena, IMSGC/WT, GeneMSA). Blue and red horizontal lines
correspond to p values of 0.001 and 3.82610-7 respectively.
doi:10.1371/journal.pone.0036140.g001
Figure 2. Manhattan plot of Macarena GWAS. Blue and red horizontal lines correspond to p values of 0.001 and 3.82610-7 respectively.
doi:10.1371/journal.pone.0036140.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36140Figure 4. Location of eQTLs of the 5p13.1 region and the SNPs associated to MS and Crohn diseases. Image from the UCSC browser
showing the chr5:39,840,547-40,924,217 (NCBI36/hg18) region. Vertical bars indicate the location of eQTLs and SNPs associated to Crohn or MS in
different studies. eQTL PTGER4 are described by Zeller et al.; eQTL PTGER4 CEU are obtained from the correlation of PTGER4 expression in the CEU
lymphoblastoid cell lines with the variants of the region; eQTL RPL37 are described by Stranger et al. and Dixon et al.; GWAS Crohn indicate the SNPs
associated with the disease in different studies [9,14,15,16]; GWAS MS indicate the SNPs associated with MS. LD plot performed with HapMap data
from CEU population.
doi:10.1371/journal.pone.0036140.g004
Figure 3. Forest plot of Meta-analysis including the GWAS datasets (with GeneMSA included as three independent substudies), and
the validation samples. MAF: Minor Allele Frequency; US: United States; UK: United Kingdom; CH: Confoederatio Helvetica/Switzerland; HL:
Holland.
doi:10.1371/journal.pone.0036140.g003
GWAS of MS Confirms a Novel Locus at 5p13.1
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36140lower LD was observed for the rs4613763 (r
2=0.14) variant. None
of the PTGER4 proximal eQTLs were genotyped in any of the
GWAS analyzed in the present work. We could impute data for
rs7725052 in the Macarena and GeneMSA datasets. The ORs
were 0.8403 and 0.8968 respectively.
Discussion
We have analysed a total 130,903 markers using data from three
GWAS and conducted several replications to detect a new marker
associated with MS. While the failure to use imputation methods
to increase the number of markers to be assessed might have
restricted the power of our study (i.e. novel signals of markers that
were not genotyped in the original GWAS would be missed), by no
means it invalidates our findings. Our main finding, rs9292777
SNP, is located within an intergenic region on 5p13.1 [23]. As
mentioned, this chromosomal region has been unequivocally
associated (i.e. meta-GWAS significance, p,5e-8) with two
autoimmune bowel diseases i.e. Crohn’s disease and ulcerative
colitis [9,14,15,16]. Furthermore, a recent meta-GWAS presented
preliminary evidence that this 5p13.1 locus could be associated to
MS [17]. Specifically, the authors observed a signal for MS located
at rs6896969 (p=2610-7). According to the 1000 genomes project
data, and employing the SNAP software, rs6896969 and
rs9292777 are 13522 bp away and can be considered reciprocal
proxies (r
2=0.901, D9=1) [24]. Therefore our results extend
previous observations and confirm unequivocally the protective
role of rs9292777, located on the 5p13.1 gene desert, for MS
phenotype.
eQTL analysis of the 5p13.1 region revealed that some SNPs in
LD with the MS associated variant rs9292777 correlated with the
expression levels of the PTGER4 gene. This expression association
has been previously suggested by Lebouille et al. who observed
that polymorphisms within this gene desert could modulate the
expression levels of PTGER4 gene, located 270 kb centromeric to
rs9292777 [14]. PTGER4 encodes the prostaglandin receptor EP4
which is a strong candidate susceptibility gene for inflammatory
bowel diseases. In fact, ptger4 knock-out mice develop severe colitis
upon dextran sodium sulphate treatment [14]. Most importantly,
recent experiments suggested that ptger4 knock-out mice are
protected against experimental autoimmune encephalomyelitis
(EAE) signs compared with control mice [25]. Notably, EAE has
proven to be a valuable model in elucidating pathogenesis as well
as identifying candidate therapies for MS [25]. So, combining
genetic and molecular data, PTGER4 pharmacological modula-
tion appears as an excellent strategy for new drug development in
human autoimmune diseases including MS.
Materials and Methods
Samples
In the present study we have analyzed three independent
genomewide datasets: Macarena, IMSGC/WT and GeneMSA
datasets and three validation collections: Sardinian, HCSC and
IPBLN samples.
The Macarena dataset consisted of a genomewide genotyping
effort (Affymetrix GeneChip Human Mapping 250K Nsp Array)
including 293 definite MS cases and 801 controls, all natives of
Spain [6]. MS cases were recruited during routine hospital visits to
the MS unit at Virgen Macarena Universitary Hospital and
diagnosed according to Poser and MacDonald criteria [26,27].
Oligoclonal IgG intrathecal secrection in CSF and/or at least 3
out of 4 MRI Barkhof criteria was also considered necessary for
inclusion in the study. All participants gave written informed
consent under Macarena Hospital Institutional Review Board.
DNA extraction from blood, PCR amplification, and genotyping
was performed at Neocodex (Seville, Spain).
The second dataset (IMSGC/WT) consisted of MS cases from
the International Multiple Sclerosis Genetics Consortium
(IMSGC) and controls from the Wellcome Trust case-control
Consortium (WTCCC). We employed the NINDS dbGaP dataset
that includes genomewide genotypes (Affymetrix GeneChip
Human Mapping 500K Array Set) for 931 individuals with MS
from the IMSGC [8], all drawn from the UK and the USA. These
MS cases were matched to a control dataset (n=2938) from the
WTCCC, deposited in the European Genotype Archive (EGA)
and genotyped with the same chip [9]. All WTCCC controls are
.99% of European origin living in the UK.
We have also employed the dbGaP GeneMSA dataset,
consisting of genomewide genotypes (Illumina Sentrix HumanHap
550K BeadChip) for 980 MS cases and 900 controls [10,28],
drawn from the USA, the Netherlands, and Switzerland.
Although these downloaded datasets had already undergone
quality control (QC) and stratification filters by the original
authors, we performed an extra layer of QC analyses on them
(described below).
In order to validate the most significant results (top 1064 SNPs
with p-value,0,005) of a meta-analysis of the 3 GWAS datasets,
we obtained aggregated frequency data and performed a first in-
silico replication in an independent dataset of 882 MS patients and
872 controls from Sardinia, Italy [13].
The top novel SNP associated with MS was genotyped or
imputed in two independent validation samples from Spain. The
first sample (HCSC) includes 557 Spanish MS patients and 799
ethnically matched controls, mostly blood donors and staff, who
were consecutively recruited from the Hospital Clı ´nico San Carlos
(Madrid). Patients were diagnosed based on the Poser criteria and
included in the study after informed consent. Clinical features in
the MS cohort from Madrid (35% men and 65% women): mean
age at onset of 29 years and age of the patients ranging from 16 to
79 years, 36% of them were carriers of the major susceptibility
factor for MS (HLA-DRB1*1501). The mean Expanded Disability
Status Scale (EDSS) was 3.5 and approximately 10% of the
patients had father, mother or a sibling with MS. The clinical
forms distributed as follows: 7% Primary Progressive, 10%
Secondary Progressive and 75% Relapsing-Remitting. The Ethics
Committee of this Hospital approved the study.
The second sample (Instituto de Parasitologı ´a y Biomedicina
Lopez-Neyra, IPBLN) comprises 1282 MS cases and 1322 controls
from 4 hospitals and a blood bank of Andalucı ´a, specifically,
Hospital Virgen Macarena of Sevilla, Hospital Carlos Haya of
Ma ´laga, Hospital Clı ´nico Virgen de las Nieves of Granada and the
Blood Bank of Granada. The mean age at sample collection of the
cases was 29.84 (10.66 sd) years and mean age of controls at
interview was 33.43 (12.19 sd) years. The percentage of females
was 68% for cases and 68% for controls. All MS cases were
classified as RR (relapsing-remitting) or SP (secondary progres-
sive). All patients were ascertained to have definite MS according
to the Poser or MacDonald criteria [26,27]. The study was
approved by the Ethics Committees of each of the hospitals
participating in the study and written informed consent was
obtained from all participants. Genotyping was performed using
the TaqmanH SNP Genotyping Assay (Applied Biosystems)
C_30119807_10 (rs9292777)
Quality Control (QC) analyses. We performed an extensive
quality control on these datasets, using Affymetrix Genotyping
Console software (http://www.affymetrix.com) and Plink [11].
Only individuals with a sample call rate above 93% were later re-
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(BRLMM) distance algorithm, ran with default parameters, which
improves call rates in most samples. Self-reported sex was
compared to sex assigned by chromosome X genotypes, and
discrepancies were resolved or samples removed. The program
Graphical Representation of Relationships (GRR) [29] was used
to check sample relatedness and to correct potential sample
mixups, duplications, or contaminations. SNPs were selected to
have a call rate above 95% (in each case, control, and combined
group, within each dataset), and a minor allele frequency above
1% (again in each case, control, and combined group, within each
dataset). SNPs that deviated grossly from Hardy-Weinberg
equilibrium (p-value,10
24) in control samples were also removed.
We also removed SNPs with a significantly different rate of
missingness (p-value,5610
24) between case and control samples
within each dataset.
To ensure all SNPs across all datasets were typed according to
the same DNA strand, each dataset was normalized using
HapMap as the reference set. We merged each study with the
HapMap CEU samples and compared genotype calls. SNP calls
were flipped (if typed on opposite strand) or removed (if strand
could not be undoubtedly assigned) as necessary. We also removed
SNPs that were significantly associated with ‘‘study status’’. That
is, we labeled individuals from each study as cases and HapMap
CEU individuals as controls, and removed SNPs with p-values
smaller than 10-6 in a test for association.
Principal Components (PC) analysis. Principal compo-
nents analysis was carried out with EIGENSOFT [7,30], to
evaluate population admixture within each population, and to
identify individuals as outliers. We ran the SMARTPCA program
with default parameters, excluding chromosome X markers. To
minimize the effect of LD in the analysis, we also excluded
markers in high LD (with the indep-pairwise option in Plink) and
long-range LD regions reported previously or detected in our
population. Individuals identified as outliers (6 standard deviations
or more along one of the top ten principal components) were
removed from all subsequent analyses. PC analysis was run within
each dataset, and also together with other HapMap European and
worldwide populations to detect individuals of different ethnicities.
Overall, we removed 7 cases and 34 controls from the Macarena
study, 45 cases and 5 controls from the IMSGC/WTCCC dataset,
and 25 cases and 42 controls from the GeneMSA project.
Imputation
Because two of the three datasets applied Affymetrix genotyping
technology, we imputed the Affymetrix SNPs on all the
participants in the GeneMSA study. Using the original Illumina
genotypes for the GeneMSA participants, and HapMap reference
genotypes (60 unrelated CEU samples), we imputed all of the
Affymetrix 500K SNPs using two different methodologies: Plink
[11] and MaCH [31]. Genotype calls with high quality scores
(info.0.8 in Plink and r
2.0.3 in MaCH) and consistently called
with both methodologies were used in subsequent association
analyses.
After all these quality control and preparatory steps, the
Macarena study kept 195,035 SNPs for 286 cases and 767
controls; the IMSGC/WTCCC dataset kept 312,869 SNPs for
886 cases and 2933 controls; and the GeneMSA dataset contained
2,649,462 SNPs in 955 cases and 858 controls. The three datasets
had 130,903 SNPs in common, which were then used in
association analyses. Additionally, rs9292777 was imputed in the
HCSC sample from surrounding SNPs available on this sample
using the same methodology described above.
Association Analysis. Single-locus allelic (1 df) association
analysis within each independent GWAS sample, and of the
combined sample, was carried out using Plink [11]. The genomic
inflation factor was also estimated, with Plink, for each dataset
(Macarena:1.13; GenMSA:1.02; IMSGC/WT:1.16). We also
carried out a meta-analysis of all three datasets using Plink. The
top 1064 most significant SNPs (p,0.005) resulting from this
meta-analysis were selected for replication using aggregated
frequency data from an Italian sample, and performed a meta-
analysis of these SNPs in the four populations. The resulting novel
SNP (rs9292777) was imputed and genotyped respectively in two
independent samples ascertained from the Spanish population. A
final meta-analysis and Forest plot for this marker including
estimates from the GWAS datasets, plus the validation samples
was done with Stata 10.0 (College Station, TX) metan command.
Expression association analysis and multiple test
correction
We used Spearman’s correlation to test for associations in cis
between SNP genotypes and probe expression levels in each
population. This method has been previously shown to produce
robust results and avoids the effect of outliers in gene expression
values [32]. We analyzed the SNPs from the 1000 Genomes
project included between chr5: 39885067- 40883829 (Build 37).
Significance thresholds for each gene were assigned after 1000
permutations of expression values relative to genotypes. Compu-
tation of the Spearman correlation test has been performed with
Genetranssoc (http://bios.ugr.es/Genetranassoc/), a c++ software
with an analogous implementation of the Spearman coefficient in
the statistical package R which also computes statistical signifi-
cance using permutation tests.Reported eQTL were assessed by
http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/.
Supporting Information
Figure S1 Samples used in the different analyses. This
flow-chart describes the samples used in the different analyses. It
starts with three initial GWAS which after extensive quality
control yielded a total of 2,127 cases and 4,558 controls. Meta-
analysis using 130,903 SNPs common to these samples was done
and SNPs with a p value below 0.001 in this analysis were
requested from the Sardinian GWAS. A new meta-analysis was
done adding these new data. Only previously unreported SNPs
with a p-value below 3.82610-7 in this analysis were chosen for a
final validation. Only one marker (rs929777) met the criteria and
was analysed in a final meta-analysis that included the previous
four samples and two new validation samples (HSCS and IPBLN).
The final result of this analysis is the main finding of our study
(rs929777, ORpooled=0.84; 95%CI: 0.80–0.89; p=1.36610-9).
(PPTX)
Figure S2 Plots of the PTGER4 expression levels respect to the
genotypes of two MS-risk variants and the PTGER4 eQTL. In all
plots, expression levels are represented for the three genotype
groups. Box plots of expression data from normalized results of
ILMN_1795930 (PTGER4) probe generated by Illumina Human-
6 v2 Expression BeadChip (EMBL-EBI database, http://www.ebi.
ac.uk/arrayexpress/, ID projects E-MTAB-198). P-values are
calculated by Kruskal Wallis Test.
(TIF)
Figure S3 LD plots of the 5p13.1 region eQTLs and the
GWAS- SNPs associated with Crohn and MS. Data are from
HapMap III CEU population. LD by r
2.
(TIF)
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PETGR4 expression in different human populations.
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